Invitro Apramycin Activity against multidrug-resistant Acinetobacter baumannii and Pseudomonas aeruginosa

Diagn Microbiol Infect Dis. 2017 Jun;88(2):188-191. doi: 10.1016/j.diagmicrobio.2017.03.006. Epub 2017 Mar 16.

Abstract

The in vitro activity of apramycin was compared to that of amikacin, gentamicin, and tobramycin against multidrug-resistant, extensively drug-resistant, and pandrug-resistant Acinetobacter baumannii and Pseudomonas aeruginosa. Apramycin demonstrated an MIC50/MIC90 of 8/32μg/ml for A. baumannii and 16/32μg/ml for P. aeruginosa. Only 2% of A. baumannii and P. aeruginosa had an MIC greater than an epidemiological cutoff value of 64μg/ml. In contrast, the MIC50/MIC90 for amikacin, gentamicin, and tobramycin were ≥64/>256μg/ml for A. baumannii with 57%, 95%, and 74% of isolates demonstrating resistance, respectively, and the MIC50/MIC90 were ≥8/256μg/ml for P. aeruginosa with 27%, 50%, and 57% of strains demonstrating resistance, respectively. Apramycin appears to offer promising in vitro activity against highly resistant pathogens. It therefore may warrant further pre-clinical study to assess potential for repurposing as a human therapeutic and relevance as a scaffold for further medicinal chemistry exploration.

Keywords: Acinetobacter; Activity spectrum; Aminoglycoside; Apramycin; Pseudomonas aeruginosa; Repurposing.

Publication types

  • Comparative Study

MeSH terms

  • Acinetobacter baumannii / drug effects*
  • Acinetobacter baumannii / isolation & purification
  • Amikacin / pharmacology*
  • Animals
  • Anti-Bacterial Agents / pharmacology*
  • Drug Resistance, Multiple, Bacterial
  • Gentamicins / pharmacology*
  • Humans
  • Microbial Sensitivity Tests
  • Nebramycin / analogs & derivatives*
  • Nebramycin / pharmacology
  • Pseudomonas aeruginosa / drug effects*
  • Pseudomonas aeruginosa / isolation & purification
  • Tobramycin / pharmacology*

Substances

  • Anti-Bacterial Agents
  • Gentamicins
  • Nebramycin
  • apramycin
  • Amikacin
  • Tobramycin